isabelobrien, Author at European Medical Journal - Page 46 of 66

Is the biotech boom on thin ice?

After dizzying heights of investment during the pandemic, biotechs have observed a slump, but the future may look more promising.

Artificially intelligent drug discovery

AI is being implemented into drug development to free up time, money and manpower, but how can humans and computers work together?

Embracing pharma's digital transformation

In his first regular column for GOLD, Davidek Herron discusses digital transformation in pharma and pursuing operational excellence.

An opportunity to crack the opioid crisis

With opioid abuse showing little sign of abating, what role can pharma play in addressing the crisis?

Pharma in Kenya

Kenya is home to a budding pharma sector, but the country still faces access to medicine challenges. What are they, and how can pharma help?

First RSV vaccine for older adults earns pivotal Phase 3 results

A first-in-class vaccine for respiratory syncytial virus has shown to be highly efficacious in a Phase III trial, GSK has announced.

Promising outlook for integrating young talent in pharma

Collaboration between the pharmaceutical industry and academia is on the rise, according to a recent survey from the ABPI.

Pfizer-BioNTech assemble with the Avengers in COVID booster drive

Pfizer and BioNTech collaborate with Marvel on a comic encouraging COVID-19 booster vaccinations in the US.

The impact of global instability

From R&D operations to manufacturing efforts, this infographic examines how the pharma sector is being affected by current global instability due to political turmoil and soaring energy prices.

The biotech rise, fall and rebound

This infographic reflects on the evolution of the biotech sector since 2016, tracking rising revenues, investment cuts and drugs that are making it to market.